Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma
This is a randomized Phase III study to evaluate efficancy of weekly cisplatin or nedaplatin concurrent with Intensity-modulated radiation therapy in Nasopharyngeal Carcinoma (NPC).
Nasopharyngeal Carcinoma
DRUG: Nedaplatin|DRUG: Cisplatin
Response rate, 2 years|Progress-free survival, 2 years
Tumor response, radiotherapy in 2 week、4 week、7 week|Overall survival, 2 years
This is a randomized Phase III study to evaluate efficancy of weekly cisplatin or nedaplatin concurrent with Intensity-modulated radiation therapy in Nasopharyngeal Carcinoma (NPC).